Opinion|Videos|July 11, 2024
Clinical study of ctDNA-based MRD detection and INTERCEPT program update
The panel examines recent studies from the INTERCEPT program investigating the utility of circulating tumor DNA (ctDNA) for minimal residual disease (MRD) detection in colorectal cancer (CRC).
Advertisement
Episodes in this series
- Please describe some recent studies exploring the utility of ctDNA in CRC
- Dr Dasari: INTERCEPT program: ctDNA testing for MRD in CRC
- Association of positive ctDNA-based MRD assays during surveillance and undiagnosed concomitant radiographic recurrences CRC (Dasari, et al. ASCO 2023. Abstract 3522.)
- Results from a prospective real-world clinical cohort (Maddalena, et al. ASCO GI 2024. Abstract 27.)
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
CD19 CAR T Cell Therapy for Treatment-Refractory Seropositive Rheumatoid Arthritis: A Phase 1 Trial
3
Outpatient Treatment-Related Toxicity After Hospital Discharge Among Patients Receiving Lifileucel for Advanced Melanoma
4
Predicting Severe Immune-Related Toxicities in Lung Cancer Immunotherapy
5